The objective of this Special Report is to catalog genetic tests and measures of gene activity that are currently under study for pharmacogenomic applications. Pharmacogenomics will be broadly interpreted to include detecting the specific molecular targets of the newer, "targeted" therapies to select patients likely to respond, as well as detecting other pharmacodynamic markers that influence targeted therapy response. Molecular indicators of variability in response or toxicity to standard chemotherapy drugs will also be reviewed. This Report will also provide a more detailed summary of the supporting data for a few illustrative examples. The tests identified in this Report are not comprehensive, but rather reflect the greatest research activity and in most cases are commercially available. Further, only tests developed from candidate genes will be examined; microarray pattern analysis and the development of predictive panels composed of many genetic markers are beyond the scope of this Report.